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Abstract 11 
A novel method to improve the proliferation activity of C2C12 cell by bovine milk fat 12 
globule membrane (MFGM) protein was established in this study. The MFGM protein 13 
was extracted and isolated into 4 fractions by an electric cream separator, and purified 14 
by cellulose DEAE-52 column. Fraction 2, accounted for 57.8% of total MFGM protein, 15 
and was used in the following study. MTT assay showed that it induced cell 16 
proliferation activity, increased cell survival rate and cell number using flow cytometer 17 
and fluorescence microscope analysis. There were only subtle changes in morphology 18 
as observed by confocal scanning laser microscopy, but the number of mitochondria 19 
were significantly increased by transmission electron microscopy analysis respectively. 20 
Furthermore, the mRNA expression of MyoD, cyclinD1, p70S6K and mTOR were up-21 
regulated by utilizing quantitative real-time PCR assay, and the activation of Akt and 22 
mTOR phosphorylation was up regulated by using Western blot assay. The main protein 23 
in fraction 2, assayed by 1-D gel electrophoresis and MALDI TOF-TOF, was identified 24 
as milk fat globule-EGF factor 8, the content was 65.6% of total protein in fraction 2. 25 
The results elucidate a new molecular mechanism of MFGM protein fraction 2: the 26 
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activation of the Akt signal pathway in promoting cell proliferation. 27 
Keywords: MFGM protein; proliferation; C2C12 cell; milk fat globule-EGF factor 8; 28 
Western blot; Akt signal pathway 29 
1. Introduction 30 
    Sarcopenia is defined as the deficiency of both muscle mass and its function.1, 2 It is 31 
caused by an imbalance of protein degradation and synthesis.3 It is accompanied by a 32 
loss of strength which can compromise the functional abilities. Eventually, skeletal 33 
muscle strength declines, equilibrium ability and metabolic rate reduce.4 C2C12 mouse 34 
skeletal muscle cell has been wildly used as a sarcopenia model to study myoblast 35 
differentiation, neuromuscular junction formation.5 Increasing C2C12 muscle cell 36 
apoptosis declines in regenerative potential, also contributes to aging-associated 37 
sarcopenia.6 Thus a combined approach of increasing regenerative potential and 38 
proliferation activity, may present a framework for therapeutic intervention of 39 
sarcopenia. Histological, biochemical and molecular biological research have shown 40 
that sarcopenia is linked with several risk factors, e.g. hormone level changes, oxidative 41 
injury, cell apoptosis, as well as poor dietary protein intake etc.3, 4, 7 These factors affect 42 
the synthesis and decomposition of muscle protein.  43 
    Dairy protein-derived branch chain amino acids, have shown the enhancement of 44 
muscle protein synthesis, increasing lean body mass and improvement of skeletal 45 
muscle function.8 Studies also showed that the phosphorylation of mTOR, and its 46 
downstream targets implicated in translation/initiation of P7S6K.9 Milk fat globule 47 
membrane (MFGM), the major nutrient component (about 0.2%) of raw milk, is a 48 
mixture consisting primarily of lipids and membrane-specific proteins.10 Except for its 49 
effect of anticancer, cholesterol lowering, anti-bacterial toxins and anti-infection etc, 50 
MFGM attracts much attention in protection against sarcopenia.11 In senescence-51 
accelerated P1 mice, which is a naturally occurring animal model for accelerated aging 52 
after normal development and maturation, exercise plus dietary MFGM can improve 53 
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muscle function through neuromuscular development.12 Clinical trials in frail women13 54 
or in healthy adults 14 have both shown that the supplementation with MFGM alone, or 55 
combined with exercise did reverse the deficits in muscle mass, function, and improved 56 
muscle mass and strength. However, there were several hundreds of proteins identified 57 
in MFGM, e.g. 268 in human milk,15 269 15 and 966 16 in bovine milk. Their functions 58 
are related to lipid metabolism (e.g. AGT, A0MBP), inflammation (e.g. APOA4, 59 
BTN1A1) and immunity (e.g. CD14, CD36), etc.16  60 
    In this study, bovine MFGM protein was extracted and isolated by an electric cream 61 
separator, and purified by cellulose DEAE-52 column. MTT assay was then used to 62 
screen the best effect of MFGM protein fraction on cell proliferation. The effect of 63 
MFGM protein on cell proliferation, apoptosis, morphology, as well as cell mRNA and 64 
protein expression were further analysed, in order to explore its mechanism of 65 
preventing sarcopenia in the C2C12 cell model. 66 
2 Materials and methods 67 
2.1 Materials and chemicals 68 
    C2C12 cell was supplied by Chinese Academy of Agricultural Sciences (Beijing, 69 
China). Cow’s milk was purchased from the local dairy farms (Harbin, Heilongjiang, 70 
China). Cellulose DEAE-52 column (2.6 × 60 cm) was purchased from Whatman (UK). 71 
Dulbecco’s Modified Eagle’s medium (DMEM, GIBCO, USA), fetal bovine serum 72 
(FBS) and trypsin-EDTA solution (approximately 0.25% trypsin and 0.02% EDTA) 73 
were purchased from GIBCO (USA). All other chemicals and reagents were analytical 74 
grade. 75 
2.2 Extraction of MFGM from cow’s milk 76 
    The method was based on He17 with a slight modification. Sucrose (5 g) was 77 
dissolved in fresh milk (100 ml), then centrifuged with an automatic cream separator, 78 
3500 g at 38 °C for 30 minutes. The buttermilk, was initially adjusted to pH 4.8 using 79 
0.01 mol/L HCl in order to allow MFGM to precipitate, and then neutralized with 0.01 80 
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mol/L NaOH. Finally, the MFGM pellet was resuspended, its supernatant was frozen 81 
dried and stored at -20 °C before analysis. 82 
2.3. Separation and purification of MFGM protein 83 
    The method was described by Wang18 with a slight modification. MFGM 84 
crude extract (0.2 g) from Section 2.2 was dissolved in PBS buffer (10 ml, pH 8.0) 85 
completely, the supernatant was loaded onto a DEAE cellulose DE-52 column followed 86 
by a linear gradient elution with NaCl (0.2 M, 0.5 M and 0.8 M ) in the same buffer, the 87 
protein fraction was collected into a vial every 5 minutes (the elution flow rate was 1 88 
ml/min) then absorbance of 4 fractions (P1, P2, P3, and P4, Figure 2A) were measured 89 
at 280 nm by HD-93-1 spectrophotometer (Purkinje General Instrument Co. Ltd., 90 
Beijing, China). The MFGM protein fractions were dialysed, and then they were further 91 
concentrated and freeze-dried; The protein content was determined by bicinchoninic 92 
acid assay kit (BCA, Solarbio, China); The yield rate of MFGM protein was calculated 93 
as in the following equation: (mass of dry MFGM protein/(mass of MFGM loaded on 94 
a DEAE cellulose DE-52 column) × 100%.  95 
2.4 Cell culture and MTT assay 96 
    C2C12 cells were grown in DMEM with 10% (v/v) FBS, 100 U/ml penicillin, and 100 97 
μg/mL of streptomycin (Invitrogen) in a humidified incubator containing 5% CO2 at 98 
37°C. Effect on cell proliferation by proteins from 4 different  fractions was firstly 99 
measured using the MTT assay.19 The C2C12 cells were inoculated with a density of 100 
5×104/ml in 96-well plates and cultured overnight at 37°C. C2C12 cells were then 101 
cultured in the same medium with 200 μg/mL of each of four fractions (Five samples 102 
per trial) for 24 h. Then 20 μl of MTT (5 mg/ml, Sigma) working solution was added 103 
to each well and incubated for 4 h at 37°C. After the MTT solution was removed, the 104 
formazan formed inside the cells was dissolved in DMSO. The absorbance was 105 
measured at 490 nm using a microplate reader (Model 550, Bio-Rad USA). Among the 106 
four fractions, fraction 2 (MFGM P2) showed the highest cell proliferation (Fig. 2C). 107 
To further test the dosage-efficacy, MFGM P2 (100, 200 or 300 μg/mL) and MFGM 108 
(200 ug/mL as a control) were further assessed, based on the above method, and cells 109 
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were cultured at 24, 48, and 72 h. The cell proliferation rate was calculated as in the 110 
following equation: (OD490 experiment group - OD490 control group)/OD490 111 
control group (Five samples per trial). 112 
2.5 Analysis of MFGM protein composition  113 
    MFGM P2 showed the biggest effect on increasing cell viability compared to other 114 
3 fractions in the MTT assay (Fig. 2C). Thus, the composition of MFGM P2 was further 115 
investigated.  116 
    MFGM P2 as well as MFGM were separated with a 1-D SDS gel (12% 117 
polyacrylamide) using a Bio-Rad electrophoresis system (Bio-Rad, USA).17 The 118 
sample (2 mg) was suspended in 200 µl of reducing buffer [250 mM pH 6.8 Tirs-HCl, 119 
10%（W/V) SDS, 2.5% (W/V) bromophenol blue, 50% (V/V) glycerol, 5% (W/V) β-120 
mercaptoethanol], and denatured for 15 min in a boiling water bath and then centrifuged 121 
at 3 000 rpm for 15 min, 10 μg protein sample was loaded onto the gel. The gel was 122 
stained with 0.1 g/L Coomassie brilliant blue R-250 and subjected to a gel imaging 123 
system using a LKB 2400 GelSCan XL software (Bio-Rad, USA). The density of a 124 
protein band with molecular weight of 45 KDa from the SDS gel was 80% of the total 125 
bands in same lane. It was excised and subjected to further analysis with MALDI-126 
TOF/TOF, the method was based on Reiz20 with a slight modification. The protein gel 127 
band was digested with trypsin (Promega), then mixed with the matrix solution of α-128 
Cyano-4-hydroxycinnamic acid. The peptides were analyzed using a 4800 Plus 129 
MALDI-TOF/TOFTM Analyzer (AB Sciex, Concord, Ontario). Ionization was 130 
performed with a diode-pumped Nd:YAG laser operated at 355 nm. The peptide ion 131 
peak selection and mass assignment were done automatically using Mascot 2.2 software 132 
in the 4800 Plus system. The components of the protein were retrieved from NCBI 133 
database.  134 
    The protein components in the band were further analysed with capillary LC-MS/MS 135 
based on the method of Churchwelll.21 The peptides were separated on an Agilent 1200 136 
chromatographic system (Agilent Technologies, Wilmington, DE) after concentrating 137 
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and desalting the products, which used a Zorbax 300SB-C18 trapping column (5 mm × 138 
0.3 mm, Agilent Technologies, Wilmington, DE) at a 4 mL min-1 flow rate using 2% 139 
(v/v) acetonitrile and 0.1% formic acid in water. The samples were separated on a 140 
Zorbax 300SB-C18 analytical column (150 mm × 75 mm, Column Technology Inc.). 141 
Solvents A and B for chromatography were 0.1% formic acid/water and 0.1% formic 142 
acid/acetonitrile water (84% of acetonitrile), respectively. The gradient elution was: 0 143 
min, 4% B; 30 min, 50% B; 34 min, 100% B; 35 min, 100% B. The flow rate was 300 144 
nL min-1. MS detection was performed using a Q Exactive mass spectrometer (Thermo 145 
Fisher). The LC-effluent was directly introduced to a Triversa NanoMate ESI 146 
(electrospray ionisation) source (Advion, Ithaca, NY, USA) with a positive mode, 147 
working in a nano-LC mode and equipped with Dchips where on a 1.55 kV voltage was 148 
supplied. The Q Exactive mass spectrometer was calibrated with caffeine, MRFA and 149 
UltraMark before measurement. Mass spectra were recorded in full scan and MS2 was 150 
triggered by a data-dependent threshold. LC-ESI-FT-MS/MS raw data were analyzed 151 
using Mascot Daemon v.2.2 (Matrixscience, London, UK).  152 
2.6 Effect of MFGM protein on cell cycle, apoptosis, cell proliferation and 153 
morphology  154 
    The C2C12 cells were inoculated in a density of 1×105 cells per well in a six-well plate 155 
and cultured overnight at 37℃. C2C12 cells were then treated with 200 μg/mL of MFGM, 156 
MFGM P2, or control (PBS) for 48 h at 37℃.  In each group, cells were harvested for 157 
the following experiments.  158 
    Cell cycle and apoptosis: the cells were harvested and fixed with 70% ice-cold 159 
ethanol overnight at -20℃. After centrifugation, cells were washed with ice-cold PBS, 160 
and stained with propidium iodide (PI, BD) solution for 30 min at room temperature in 161 
a dark environment. Cell cycle and apoptosis were analyzed using a BD FACS scan 162 
flow cytometer (Bio-Rad) and Cell-Quest software (BD Biosciences). 163 
    Cell apoptosis: the method was based on Chen22 with a slight modification. A 164 
fluorescein-conjugated Annexin V (Annexin V-FITC) staining assay was performed 165 
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according to the manufacturer’s protocol (BD Biosciences Pharmingen, San Jose, CA, 166 
USA). Briefly, cells were stained with 5 μl of Annexin V-FITC and 5 μl of PI in each 167 
sample. After incubation for 15 min at room temperature in a dark environment, the 168 
degree of apoptosis was quantified as a percentage of the Annexin V-positive and PI-169 
negative cells by flow cytometer. 170 
    Cell proliferation (survival and apoptosis cells) assay: the Hoechst 33342/PI 171 
detection kit (Solarbio). Cells were washed with PBS (pH 7.2), then incubated with 1 172 
ml of staining buffer, 5 μl of Hoechst 33342 (excitation 360 nm/emission 465 nm) 173 
buffer and 5 μl of PI staining (excitation 488 nm/emission 620 nm) buffer for 30 min at 174 
4 °C in the dark. The survival and apoptosis cells were observed using a fluorescence 175 
microscope (ZEISS, Germany) and a confocal scanning laser microscope (Leica, 176 
Germany) respectively. 177 
    Morphology examination: C2C12 cells were fixed with 4% glutaraldehydeat at 4℃ 178 
for 12 hours. The fixed cells were collected using cell scrappers followed by 179 
centrifugation at 1 000 rpm for 5 min. The cell pellets were fixed for an additional 2 h 180 
in 2.5% glutaraldehyde, and for 2 h with 1% osmium tetroxide. The cell pellets were 181 
dehydrated in ascending ethanol serial washes and embedded in Epon 812. Serial 182 
ultrathin sections were examined using Zeiss 900 electron microscope (ZEISS, 183 
Germany) with magnifications of 7 000 to 30 000. 184 
    mRNA expression of cyclin D1, MyoD, mTOR and S6K: Total RNA was isolated, 185 
then the RNAprep Pure Cell/Bacteria Kit (TIANGEN) was used for qRT-PCR analysis. 186 
cDNA was synthesized by using 3 μg of RNA with PrimeScriptTM II 1st Strand cDNA 187 
Synthesis Kit (TaKaRa) following the manufacturer’s protocol. The assay was carried 188 
out on an ABI 7300 Real-Time PCR system (Applied Biosystems) with SYBR○RPremix 189 
Ex TqaTM II (TaKaRa, Japan). Relative expression was first quantified using a standard 190 
curve, and data was normalized to GAPDH mRNA. Primers used in the study were 191 
shown as followings.22-24 GAPDH: 5'-ACCA- 192 
CAGTCCATGCCATCAC-3', 5'-TC-CACCACCCTGTTGCTGTA-3'; CyClinD: 5'-T 193 
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-AGGCCCTCAGCCTCACTC-3', 5'-CCACCCCTGGGATAAAGCAC-3'; mT-OR: 5'-194 
CTGGGACTCAAATGTGTGCAGTTC-3', 5'-GAACAATAGGGTGAATGATCCG 195 
-GG-3'; p70S6K: 5'-GGGAAGGCTTTGCAGTTTAC-3', 5'-TCCAGTCCCTCACGA 196 
-ACAAA-3'. Myod: 5'-TCAGGTGCTTTGAGAGATCGAC-3', 5'-CGAAAGGACAG 197 
-TTGGGAAGAGT-3'. 198 
2.7 Western blot assay 199 
    The C2C12 cells were treated with 200 μg/ml MFGM or MFGM P2 for 48 h at 37℃, 200 
then collected and washed twice with PBS, and homogenized in lysis buffer. Total 201 
protein was extracted and harvested by scraping with a modified Radio 202 
Immunoprecipitation Assay (RIPA) buffer and phenylmethylsulfonyl fluoride (PMSF) 203 
for 30 min. Following centrifugation 10 000 rpm at 4℃ for 15 min, the supernatant was 204 
then sonicated. Protein concentration was quantified using BCA kit. 100 μg protein was 205 
loaded onto a 1-D SDS gel (10% polyacrylamide). Then proteins were transferred to 206 
nitrocellulose filter membrane (PPLYGEN, China) using a wet electrotransfer system 207 
(Bio-Rad, USA）for 4 h at 200 mA. The membranes were blocked with 5% non-fat 208 
dry milk in Tris-buffered saline with Tween-20 (TBST) buffer for 1 h at room 209 
temperature followed by incubation with primary antibodies (Santa CruzZ，USA) for 210 
each protein, for 1 h at 37℃ or overnight at 4℃ according to the requirements. The 211 
concentrations of antibodies were GAPDH (1:500), Akt (1:500), p-Akt Ser 473 (1:800), 212 
p-mTOR Ser 2248 (1:500) respectively. The membrane was washed 3×5 min with 213 
TBST followed by incubation with anti-mouse or anti-rabbit secondary antibody (1:2 214 
000; Santa Cruz Biotechnology, Inc) at 37℃ for 1 h. The membrane was washed with 215 
TBST twice and with TBS once, 5 min each, then incubated with alkaline phosphatase 216 
until an appropriate signal level was obtained. Protein bands were detected by 217 
FluorChem Imaging Systems (Alpha Innotech, Corp., San Leandro, CA, USA). 218 
2.8 Statistical analysis 219 
   All experiments unless stated somewhere else, were tested and analyzed in triplicate. 220 
An analysis of variance (ANOVA) was identified to determine the significant 221 
differences (P < 0.05) between means. The statistical analysis was done by using a 222 
 9 
 
General Linear Model procedure of SAS 9.1.3 software from SAS Institute Inc., Cary, 223 
NC, USA. 224 
3. Results 225 
    MFGM protein was extracted by an electric cream separator, and four fractions of 226 
MFGM protein were collected by a linear gradient elution; the effect of each fraction 227 
on cell proliferation was initially assessed. Amongst four fractions, the second fraction 228 
showed the best effect based on the yield of MFGM protein and the cell proliferation 229 
rate, thus, its composition was analyzed; and its effects on cell proliferation, apoptosis, 230 
morphology, as well as cell mRNA and protein expression were further investigated 231 
(Working Flow Chart 1). 232 
 233 
Fig. 1 The flow chart of this study 234 
3.1 Protein amount in four fractions of MFGM protein and their effects on cell 235 
proliferation  236 
    MFGM protein was separated by DEAE-52 (Fig. 2A). Four fractions (P1 to P4) were 237 
collected based on elution time, and protein amount in each fraction is shown in Fig. 238 
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2B. After dialysis, the order of protein recovery rate (%) was: MFGM P2 (23.3%) > 239 
MFGM P3 (12.6%) > MFGM P4 (3.6%) > MFGM P1 (1.2%). Among the four fractions, 240 
MFGM P2 accounted for about 57.8% of total protein, even more, the proliferation of 241 
C2C12 cell in MFGM P2 was the highest among all fractions (Fig. 2C). Thus, MFGM 242 
P2 was used to carry out the following experiments. 243 
 244 
Fig. 2 The analysis of separation and screening of functional MFGM protein. A) 245 
MFGM protein separated by a cellulose DEAE-52 column; B) the yield of MFGM 246 
protein fraction; C) the effect of MFGM protein on C2C12 growth. 247 
3.2 The composition of MFGM P2  248 
MFGM MFGM P1 MFGM P2 MFGM P3 MFGM P4
-10
-5
0
5
10
15
 
 
T
h
e 
p
ro
m
o
te
 o
r 
in
h
ib
it
io
n
 o
f 
M
F
G
M
 
fr
ac
ti
o
n
 o
n
 C
2
C
1
2
 c
el
l 
g
ro
w
th
 (
%
)
(A) (B) 
(C) 
 11 
 
 249 
Fig. 3 SDS-PAGE analysis of the MFGM P2 extracted by the cellulose DEAE-52 250 
column. Lane 1: molecular weight marker; lane 2: crude extraction of MFGM; lane 3: 251 
MFGM P2 purified by the cellulose DEAE-52 column. 252 
The MFGM P2 was first analysed by 1-D SDS-PAGE (Fig. 3) followed by MALDI 253 
TOF/TOF (Fig. 4). There were eight major bands in the lane of MFGM protein, and 254 
four bands in the lane of MFGM P2, ranging from 26 to 225 kDa in molecular weight. 255 
The major protein band of 45 kDa in the MFGM P2 lane had a density of 80%, was 256 
further analysed by MALDI TOF/TOF. There were 42 proteins identified (data not 257 
shown) in the band, and among them, one protein, milk fat globule-EGF factor 8 protein 258 
(MFG-E8), was quantified as 82 % of total protein (raw data not shown) in the band. 259 
Thus, MFG-E8 accounted for 65.6% of total protein in fraction 2. This was based on 260 
the calculation of [82% (the amount of MFG-E8 in the main protein band at 45 kDa in 261 
MFGM P2) x 80% (density of MFG-E8 band to density of total protein bands)]. 262 
 263 
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 264 
Fig. 4 The analysis of MFGM protein by MALDI TOF/TOF. 265 
3.3 MTT Assay for appropriate concentration of MFGM P2  266 
 267 
Fig. 5 MTT assay analysis of the effect of MFGM and MFGM P2 on cell 268 
proliferation. 269 
C2C12 cells were treated with 100, 200 and 300 μg/mL of MFGM P2 in 96-well plates 270 
for 24, 48 and 72 h at 37℃, and cell proliferation was measured subsequently by MTT 271 
assay (Fig. 5). Results showed that the cell proliferation activity increased with time as 272 
well as with concentration, but decreased at 72 h. The proliferation rate reached at 273 
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maximum (35.8%) at 200 μg/mL at 48 h. The order of proliferation rate was shown as 274 
followings: 200 μg/mL of MFGM P2 >100 μg/mL of MFGM P2 > 200 μg/mL of 275 
MFGM > control > 300 μg/mL of MFGM P2. Thus, the concentration of 200 μg/mL 276 
MFGM P2 and incubation time at 48 h were applied to the following experiments.  277 
 3.4 The effect of MFGM P2 on cell proliferation and apoptosis 278 
    To determine the effect of MFGM P2 on the cell cycle, FACS analysis was performed 279 
in C2C12 cells treated with each of MFGM P2 (200 μg/mL) or MFGM (200 μg/mL) for 280 
48 h. Compared with the control group, the G0/G1 and S population decreased by 8.63% 281 
and 2.94%, respectively, while the G2/M population increased by 11.72% in cells 282 
treated with MFGM P2 (Fig. 6A), suggesting that MFGM P2 induces the cell cycle. 283 
However, there was a 5.12% increase in S population, and 2.93% and 2.36% decrease 284 
in G0/G1 and G2/M population in cells treated with MFGM (200 μg/mL) (Fig. 6A), 285 
suggesting that MFGM induces S-phase arrest. The results demonstrated that MFGM 286 
P2 induced the cell cycle, whereas MFGM induced S-phase arrest. 287 
    The cell apoptotic status, affected by MFGM and MFGM P2, was further observed 288 
by a fluorescence microscope, the results are shown in Fig. 6. There were less 289 
apoptosis cells stained with Annexin V-FITC-PI, but the cell density was higher in the 290 
MFGM P2 group than MFGM group (Fig. 6B); the result of flow cytometer showed 291 
that scarcely any apoptosis of C2C12 cells were found in control group, MFGM group 292 
and MFGM P2 group (Fig. 6C). The result indicated that MFGM and MFGM P2 had 293 
no toxicity effect on C2C12 cells, the result was collated with the cell cycle experiment. 294 
 14 
 
 295 
Fig. 6 The effect of MFGM protein on cell proliferation. (A) the effect of MFGM 296 
protein on cell cycle; (B) the analysis of Hoechst 33342/PI staining; (C) the effect of 297 
MFGM protein on cell apoptosis. 298 
3.5 Effect of MFGM P2 on cell morphology 299 
The effects of MFGM P2 on cell morphology and internal structure were shown in 300 
Fig. 7. The results showed that there was no difference among control group, MFGM 301 
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group and MFGM P2 group, which indicated the MFGM and MFGM P2 did not affect 302 
the surface morphology of the C2C12 cell (Fig. 7A). However, the results from 303 
transmission electron microscopy (TEM) did show that the inner structures were 304 
changed (Fig. 7B), although there was a similar morphology of the C2C12 cell in all 305 
groups (Fig. 7A).  306 
(A)  307 
   (B)  308 
Fig. 7 Transmission electron microscopy (TEM) and CLSM imaging of C2C12 cells 309 
incubated for 48 h with MFGM or MFGM P2 modified medium. (A)The analyisis of 310 
CLSM; (B) The TEM micrograph shows C2C12 with the presence of rounder shaped 311 
mitochondria (arrows). 312 
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3.6 Effect of MFGM P2 on the mRNA expression of cyclin D1, MyoD，mTOR and 313 
p70S6K; and the protein expression of Akt, p-Akt, mTOR and p-mTOR 314 
(A)  315 
(B)  316 
Fig. 8 The effect of MFGM P2 on mRNA and protein expressions of some regulators 317 
during C2C12 cell proliferation at 48 h. (A) The response of cyclin D1, MyoD, mTOR 318 
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and p70S6K mRNA levels; (B) The effects of MFGM and MFGM P2 on Akt, p-Akt 319 
Ser 473, mTOR and p-mTOR Ser 2448 expression. 320 
The mRNA levels of MyoD，cyclin D1, mTOR and p70S6K were determined by 321 
quantitative real-time PCR experiments (Fig. 8A). Compared with control group, 322 
MyoD, cyclin D1, mTOR and p70S6K mRNA levels in the MFGM group were 323 
increased by 3%, 82% (P<0.01), 10% (P<0.01) and 63% (P<0.01), respectively; 324 
Compared with the MFGM group, myoD and p70S6K levels in MFGM P2 group were 325 
significantly increased by 1.37 and 1.86 fold (both P<0.01) respectively, the cyclin D1 326 
and mTOR mRNA levels were increased by 3.5% and 5.8%, respectively. 327 
Corresponding to the results of qRT-PCR, some proteins were analysed further with 328 
Western blot (Fig. 8B). The total amount of Akt in MFGM P2 group increased 1.46 fold 329 
over control and MFGM, whereas the level of its phosphorylated form was increased 330 
1.33 fold.  331 
4 Discussion  332 
    Previous studies showed that crude MFGM could improve skeletal muscle strength 333 
or capability in animal and humans.13, 14 However, the specific protein wasn’t known 334 
yet, and  the amount of MFGM protein in dietary sources is very low, therefore, this 335 
study not only found  a way to enrich the protein but also investigated the effect and 336 
mechanism of antisarcopenia of the best effective protein, MFGM P2.  337 
    Results from Section 3.1 showed that the method successfully extracted and 338 
separated proteins into four fractions, and importantly, about 57.8% of total protein was 339 
in the second fraction, was MFGM P2.  In a 1-D gel electrophoresis of MFGM P2, 42 340 
proteins of 45 kDa were identified in the main protein band, of which MFG-E8 341 
accounted for about 82%. Thus, MFG-E8 accounted for about 65.6% of total protein in 342 
MFGM P2. MFG-E8 is known as lactadherin, a protein encoded by the MFG-E8 gene 343 
in humans. It is identified as a major glycoprotein of the milk fat globule, a protein and 344 
triglyceride rich membrane-bound vesicle secreted from the mammary epithelium 345 
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during milk production.25  In this study, rather than further extraction and purification 346 
this MFG-E8 protein, whole protein of MFGM P2 was used to analyse the 347 
antisarcopenia effect. Because MFG-E8 is composed of 65.6% of total protein, the 348 
effect of MFGM P2 was considered as a potential effect of MFG-E8, even though more 349 
research is required for verification.  350 
MTT assay suggested that MFGM P2 had both a proliferative and antiproliferative 351 
effect on C2C12 cells, the results were similar to the effect of insulin, shown by the 352 
research of Cheng23 who found that insulin has both proliferative and antiproliferative 353 
effect on C2C12 cells, depending on insulin concentration. Our results found an optimal 354 
MFGM P2 dosage for cell growth at 200 μg/mL. This dosage would be a good reference 355 
for further clinical trials. FACS analysis demonstrated that MFGM P2 induced the cell 356 
cycle, whereas MFGM induced S-phase arrest; V-FITC-PI analysis showed that 357 
although scarcely any apoptosis of C2C12 cell was found in the control group, MFGM 358 
group and MFGM P2 group, but cell density was higher in the MFGM P2 group than 359 
the MFGM group. The results indicated that MFGM P2 showed more enhancement of 360 
cell proliferation by promoting cell cycle progression and no toxicity. Therefore, 361 
MFGM P2 was more beneficial to muscle protein synthesis. 362 
Results from confocal scanning laser microscopy and TEM showed MFGM and 363 
MFGM P2 did not change the surface morphology of the C2C12 cell, but the 364 
mitochondrial number was increased in MFGM P2 group by TEM assay (Fig. 7B). 365 
Inherent or acquired mitochorndrial disorders can cause major disruption of cell 366 
survival and whole body metabolic homeostasis.26, 27 Mitochondria play crucial roles in 367 
energy metabolism.28, 29 Mitochondrial dysfunction in skeletal muscle has been 368 
considered as a crucial step in the development of metabolic diseases. Protein kinase B, 369 
also known as Akt, a serine/threonine kinase, is a critical signaling component for the 370 
regulation of cellular metabolism, growth, and survival in multiple systems.30 The 371 
activity of Akt is in response to numerous stimuli, e.g. growth factors and hormones. 372 
Akt can also be activated by increasing intracellular Ca2+ or cAMP, which occur with 373 
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increasing muscle contractile activity.31  374 
Our findings showed that promoting cell proliferation by MFGM P2 might be 375 
related to Akt signal pathways. Results showed that MFGM P2 regulated the 376 
transcription and the expression of cyclin D1, MyoD, p70S6k, mTOR and Akt to affect 377 
cell growth. As 65.6% of protein in MFGM P2 was MFG-E8, we deduced that the 378 
action caused by MFGM P2 was mainly from MFG-E8. Previous research reported the 379 
role of MFG-E8 in cell growth, invasion, and metastasis.32 MFG-E8 promoted 380 
resistance to apoptosis, an epithelial mesenchymal transition, and angiogenesis through 381 
the activation of the PI3K/Akt/mTOR signal pathways. However, there has been no 382 
report about the effect of MFG-E8 on C2C12 cell growth.  383 
    MyoD is considered to be a marker for terminal specification to the muscle lineage.33 384 
Its activity has been shown to correlate with the induction of the CDK inhibitor p21.34 385 
PI3K/Akt mediated signal pathway can increase the MyoD by enhancing its 386 
transcriptional activity.35 Here, we demonstrated that MFGM P2 could induce MyoD 387 
expression and cell growth. Results also showed that MFGM P2 regulated the 388 
transcription and expression of cyclin D1 to affect cell growth. Cyclin D1 plays a key 389 
role in controlling the cell cycle progression.36 It regulates progression through the G1 390 
phase of the cell cycle by simulating the activity of the cyclin D-dependent kinases 391 
(CDK) 4 or 6.37 The activities of CDK serve to integrate extracellular signaling during 392 
the G1 phase with the cell-cycle engine that regulates DNA replication and mitosis.38 393 
Akt can regulate Cyclin D1 and CDK 4 activity and induce cell proliferation.39 The 394 
relevance of the MFG-E8-cyclin D1 pathway in the proliferation of vascular smooth 395 
muscle cells has also been demonstrated by Haruka40, who showed that MFG-E8 396 
expression is associated with a tendency for increasing expression of vascular smooth 397 
muscle cell proliferation marker, cyclin D1. 398 
     Akt activation prevents muscle atrophy including sarcopenia.41 Moreover, the 399 
activation of Akt in myoblasts increases their cell proliferation rate and rescues them 400 
from cell death. mTOR is one of the key kinases in cell signal transduction, playing an 401 
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important role in cell growth, metabolism and the cycle process. Previous research 402 
found that PI3K mediates G1 progression and cyclin expression through activation of 403 
the AKT/mTOR/p70S6K signaling pathway,42 mTOR regulation protein synthesis, via 404 
phosphorylation and activation of p70S6K.43 Phosphorylation of p70S6K leads to the 405 
activation of pathways promoting protein synthesis and translation initiation.44-46 So 406 
essentially, the mTOR signaling pathway is critical for cellular growth and survival in 407 
skeletal muscle, and is activated in response to growth factors such as insulin-like 408 
growth factor-I.47, 48 In the current study, phosphorylation of Akt increased significantly 409 
with incubation in MFGM P2 (Fig. 8). A significantly higher Akt-dependent 410 
phosphorylation of mTOR was observed after 48 h with MFGM P2 treatment. The 411 
result indicated that MFGM P2 treatment has a proliferation effect on translation via 412 
the proliferation of Akt and mTOR phosphorylation, which is necessary for the 413 
blockade of MFG-E8 induced translational change.  414 
The results demonstrated that MFGM P2 could up-regulate mRNA levels of 415 
Cyclin D1, MyoD,  mTOR and p70S6K expression, and protein levels of Akt and 416 
mTOR expression. The mechanism of MFGM P2 on cell proliferation might be through 417 
PI3K/Akt/mTOR/p70S6K signal pathway. This may be caused by the effect of MFG-418 
E8 via regulation on the expression of the Akt/mTOR signal pathway. To the best of our 419 
knowledge, there were no report about MFGM protein promote C2C12 cells 420 
proliferation previously, in this study, we describe this growth function of MFGM P2, 421 
and discuss its downstream target, Cyclin, MyoD, p70S6k, mTOR and Akt, which play 422 
important roles in cell proliferation. 423 
Conclusion 424 
    Our data suggest that MFGM protein extracted and isolated by an electric cream 425 
separator, and purified by cellulose DEAE-52 column is an effective way, which can 426 
potently promote cell growth and inhibit apoptosis of C2C12 cells by upregulation of the 427 
expression of Akt and mTOR protein kinase. These findings represent a novel 428 
mechanism of MFGM protein in cell growth and have new clinical implications in 429 
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designing MFGM protein therapies. 430 
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